Creative Financial Designs Inc. ADV Sells 32,370 Shares of Pfizer Inc. (NYSE:PFE)

Creative Financial Designs Inc. ADV reduced its position in Pfizer Inc. (NYSE:PFE - Free Report) by 72.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,512 shares of the biopharmaceutical company's stock after selling 32,370 shares during the quarter. Creative Financial Designs Inc. ADV's holdings in Pfizer were worth $317,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of PFE. Brighton Jones LLC grew its position in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. Proficio Capital Partners LLC boosted its position in shares of Pfizer by 2,193.2% during the 4th quarter. Proficio Capital Partners LLC now owns 225,584 shares of the biopharmaceutical company's stock valued at $5,985,000 after acquiring an additional 215,747 shares during the last quarter. Versor Investments LP purchased a new position in shares of Pfizer during the fourth quarter worth about $570,000. Finally, Tower Bridge Advisors increased its position in shares of Pfizer by 2.0% in the fourth quarter. Tower Bridge Advisors now owns 64,997 shares of the biopharmaceutical company's stock worth $1,724,000 after purchasing an additional 1,296 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of research reports. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Cantor Fitzgerald began coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, Pfizer has an average rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Trading Down 0.2%

Shares of PFE stock opened at $24.20 on Friday. The business has a 50-day moving average of $23.46 and a 200 day moving average of $24.84. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The stock has a market capitalization of $137.56 billion, a PE ratio of 17.53, a P/E/G ratio of 0.88 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the previous year, the company posted $0.82 earnings per share. The business's revenue was down 7.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.11%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.